Frontlight ResearchEarly access
TerminatedPhase 4
Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).
Key facts
- Who runs it
- David Binion, MD
- Where
- Pittsburgh, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 4
- People taking part
- 19 people enrolled
- Started
- 14 Oct 2021
- Ended
- 31 May 2024
- Type of study
- Interventional
- Treatments tested
- Bezlotoxumab
- Record updated
- 5 June 2025
- Why it stopped
- Sponsor's decision
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- >18 years old
- active CDI receiving therapy
- diagnosis of IBD
- and history of CDI
Who cannot take part
- history of colectomy
- history of preexisting congestive heart failure
- past cardiac history
- <18 years old
- no IBD
- no CDI
- pregnant or nursing women
- TCP<50
Where in United States
- University of Pittsburgh Medical CenterPittsburgh, United States
About the trial
What the trial wants to find out
The study will compare the effectiveness of Bezlotoxumab in individuals with active C. diff ( Clostridium difficile) infection who are diagnosed with Inflammatory Bowel Disease.
The group in the trial
- Open labelOther group
Single arm
Treatment: Bezlotoxumab
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 5 June 2025